Literature DB >> 18715779

Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal.

Nilesh Shah1, Brendan Pang, Khay-Guan Yeoh, Shannon Thorn, Chien Shing Chen, Michael B Lilly, Manuel Salto-Tellez.   

Abstract

In vitro experiments have shown the PIM1 kinase to have diverse biological roles in cell survival, proliferation and differentiation. In humans, PIM1 is often expressed in both normal and transformed cells. The PIM1 kinase is a true oncogene implicated in early transformation and tumour progression in haematopoietic malignancies and prostate carcinomas. It is associated with aggressive subgroups of lymphoma, is a marker of poor prognosis in prostate carcinomas and has been suggested to have a role in hormone insensitivity of prostate malignancies. PIM1 has a possible role in other carcinomas with 6p21 genomic alterations. On one hand, PIM1 (due to its role in malignancy) appears to be a promising target for drug development programmes but, on the other hand, the complexity of its molecular structure has posed challenges in the development of PIM1 inhibitors. In this review we discuss PIM1 expression in human tissues (including some new data from our laboratory), its role in human malignancies, as well as the possibilities and challenges in the development of target therapy for PIM1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18715779     DOI: 10.1016/j.ejca.2008.06.044

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  60 in total

1.  Targeting diverse signaling interaction sites allows the rapid generation of bivalent kinase inhibitors.

Authors:  Zachary B Hill; B Gayani K Perera; Simeon S Andrews; Dustin J Maly
Journal:  ACS Chem Biol       Date:  2011-12-22       Impact factor: 5.100

2.  Regulation of Skp2 levels by the Pim-1 protein kinase.

Authors:  Bo Cen; Sandeep Mahajan; Marina Zemskova; Zanna Beharry; Ying-Wei Lin; Scott D Cramer; Michael B Lilly; Andrew S Kraft
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

3.  Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival.

Authors:  Susann Herzog; Matthias Alexander Fink; Kerstin Weitmann; Claudius Friedel; Stefan Hadlich; Sönke Langner; Katharina Kindermann; Tobias Holm; Andreas Böhm; Eskil Eskilsson; Hrvoje Miletic; Markus Hildner; Michael Fritsch; Silke Vogelgesang; Christoph Havemann; Christoph Alexander Ritter; Henriette Elisabeth Meyer zu Schwabedissen; Bernhard Rauch; Wolfgang Hoffmann; Heyo Klaus Kroemer; Henry Schroeder; Sandra Bien-Möller
Journal:  Neuro Oncol       Date:  2014-08-25       Impact factor: 12.300

4.  IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines.

Authors:  Katherine M Block; Neale T Hanke; Erin A Maine; Amanda F Baker
Journal:  Pancreas       Date:  2012-07       Impact factor: 3.327

5.  The Pim protein kinases regulate energy metabolism and cell growth.

Authors:  Zanna Beharry; Sandeep Mahajan; Marina Zemskova; Ying-Wei Lin; Baby G Tholanikunnel; Zuping Xia; Charles D Smith; Andrew S Kraft
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

6.  The rise of a ribosomopathy and increased cancer risk.

Authors:  Friedrich Luft
Journal:  J Mol Med (Berl)       Date:  2009-12-12       Impact factor: 4.599

7.  Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment.

Authors:  Linhua Jin; Yoko Tabe; Hongbo Lu; Gautam Borthakur; Takashi Miida; Hagop Kantarjian; Michael Andreeff; Marina Konopleva
Journal:  Cancer Lett       Date:  2012-10-02       Impact factor: 8.679

8.  Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.

Authors:  Renate De Smedt; Sofie Peirs; Julie Morscio; Filip Matthijssens; Juliette Roels; Lindy Reunes; Beatrice Lintermans; Steven Goossens; Tim Lammens; Nadine Van Roy; Aurore Touzart; Silvia Jenni; Yi-Chien Tsai; Federica Lovisa; Lara Mussolin; Valentina Serafin; Filip Van Nieuwerburgh; Dieter Deforce; Anne Uyttebroeck; Thomas Tousseyn; Birgit Burkhardt; Wolfram Klapper; Barbara De Moerloose; Yves Benoit; Elizabeth Macintyre; Jean-Pierre Bourquin; Giuseppe Basso; Benedetta Accordi; Beat Bornhauser; Jules Meijerink; Peter Vandenberghe; Pieter Van Vlierberghe
Journal:  Haematologica       Date:  2018-08-03       Impact factor: 9.941

9.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

10.  A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.

Authors:  Ying-Wei Lin; Zanna M Beharry; Elizabeth G Hill; Jin H Song; Wenxue Wang; Zuping Xia; Zhenhua Zhang; Peter D Aplan; Jon C Aster; Charles D Smith; Andrew S Kraft
Journal:  Blood       Date:  2009-11-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.